SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 32.31+1.4%Nov 26 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: aknahow who wrote (14749)9/19/2000 6:53:51 PM
From: Cacaito  Read Replies (2) of 17367
 
Overall an excellent study both in design an execution under the circumstances of big logistical problems like recruitment of patients in a disease that is rare, early use of the drug is imperative, rapidity of disease progression, informed consent, and the need for "slow infusion" of the drug.

Maybe a one fast dose that is not eliminated fast in the body, or a fast dose at the local centers before reaching the major center then the infusion (baboons were pre treated if I remember well).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News